Emcure Pharmaceuticals Ltd (NSE: EMCURE, BSE: 544210) is a Pune, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹34,533 Cr, it ranks #253 by market cap among the 6,137 Indian listed companies on FinBizNet, and #3 of 63 in Pharmaceuticals. At ₹1,770.40 (as of 25 Oct 2026), the share price is 15.7% below its 52-week high of ₹2,100.70 and 35.5% above its 52-week low of ₹1,306.50. The share price is up 31.1% over one year and down 5.9% over three months.
| Current Price | ₹1,770.40 |
|---|---|
| Market Cap | ₹34,533 Cr |
| NSE Symbol | EMCURE |
| BSE Code | 544210 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 36.3 |
| Return on Equity | 19.57% |
| Return on Assets | 9.62% |
| 52-Week Range | ₹1,306.50 – ₹2,100.70 |
| 1-Year Price Change | +31.1% |
| 3-Month Price Change | -5.9% |
| Beta (1Y) | -0.03 |
| Dividend Yield | 0.20% |
| Headquarters | Pune, Maharashtra |
| Website | www.emcure.com |
| Revenue | ₹2,580 Cr |
|---|---|
| Net Profit | ₹292 Cr |
| Net Margin | 11.3% |
| EPS (Basic) | ₹15.50 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
1. Pharmaceuticals-This segment engages in the development, manufacture, and marketing of various pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Astrazeneca Pharma India Ltd. | ₹14,915 Cr | 80.6 | 22.82% | ₹683 Cr | -34.5% |
Listed by market capitalisation. Ratios are shown for context only.
Emcure Pharmaceuticals Ltd is trading at ₹1,770.40, with a market capitalisation of ₹34,533 Cr.
Emcure Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Emcure Pharmaceuticals Ltd has a P/E of 36.3 and a return on equity of 19.57%.
Emcure Pharmaceuticals Ltd is listed on the NSE under the symbol EMCURE and on the BSE under the scrip code 544210.
Emcure Pharmaceuticals Ltd's share price is up 31.1% over one year and down 5.9% over three months. Its 52-week range is ₹1,306.50 to ₹2,100.70.
In Q1 FY27, Emcure Pharmaceuticals Ltd reported revenue of ₹2,580 Cr and net profit of ₹292 Cr, with basic EPS of ₹15.5 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.